帕博西尼(PD-0332991),一种选择性CDK4/6抑制剂,在肝细胞癌临床前模型中限制肿瘤生长
该研究在多种肝细胞癌临床前模型中评估帕博西尼的疗效。帕博西尼通过促进可逆性细胞周期阻滞抑制细胞增殖,RB1缺失决定原发性和获得性耐药,RB1功能缺失特征见于<30%的HCC样本。帕博西尼单用或联合索拉非尼可抑制体内肿瘤生长并显著提高生存率。
要点
- 帕博西尼通过可逆性细胞周期阻滞抑制人肝癌细胞系增殖。
- RB1缺失决定对帕博西尼的原发性和获得性耐药。
- 帕博西尼单用或联合索拉非尼在体内抑制肿瘤生长并显著提高生存率。
核心结论
- 帕博西尼在肝细胞癌临床前模型中显示令人鼓舞的结果,代表一种新的治疗策略,可单用或尤其与索拉非尼联合使用。
- 帕博西尼可能使RB1功能完好的肿瘤患者获益,此类患者占所有HCC患者的70%。
研究设计与样本
- 在人肝癌细胞系、人HCC离体样本、基因工程小鼠肝癌模型和人HCC异种移植体内模型中研究帕博西尼对细胞增殖、细胞衰老和细胞死亡的影响。
- 在人肝癌细胞系和人HCC样本中通过蛋白和基因表达分析评估对帕博西尼原发性和获得性耐药的机制。
主要发现
- 帕博西尼通过促进可逆性细胞周期阻滞抑制人肝癌细胞系增殖。
- 对帕博西尼的原发性和获得性耐药由RB1缺失决定。
- RB1功能缺失特征见于<30%的HCC样本。
- 帕博西尼单用或联合索拉非尼在体内抑制肿瘤生长并显著提高生存率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Palbociclib, a well-tolerated and selective CDK4/6 inhibitor, has shown promising results in the treatment of retinoblastoma (RB1)-positive breast cancer. RB1 is rarely mutated in HCC, suggesting that palbociclib could potentially be used for HCC therapy. Here, we provide a comprehensive characterisation of the efficacy of palbociclib in multiple preclinical models of HCC. DESIGN: The effects of palbociclib on cell proliferation, cellular senescence and cell death were investigated in a panel of human liver cancer cell lines, in ex vivo human HCC samples, in a genetically engineered mouse model of liver cancer, and in human HCC xenografts in vivo. The mechanisms of intrinsic and acquired resistance to palbociclib were assessed in human liver cancer cell lines and human HCC samples by protein and gene expression analyses. RESULTS: Palbociclib suppressed cell proliferation in human liver cancer cell lines by promoting a reversible cell cycle arrest. Intrinsic and acquired resistance to palbociclib was determined by loss of RB1. A signature of 'RB1 loss of function' was found in <30% of HCC samples. Palbociclib, alone or combined with sorafenib, the standard of care for HCC, impaired tumour growth in vivo and significantly increased survival. CONCLUSIONS: Palbociclib shows encouraging results in preclinical models of HCC and represents a novel therapeutic strategy for HCC treatment, alone or particularly in combination with sorafenib. Palbociclib could potentially benefit patients with RB1-proficient tumours, which account for 70% of all patients with HCC.
引用
- Bollard J, Miguela V, Ruiz de Galarreta M, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2016. PMID: 27849562. doi:10.1136/gutjnl-2016-312268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。